Gene variant linked to autism spectrum disorder

Monday, 09 August, 2021

Gene variant linked to autism spectrum disorder

Researchers from the RIKEN Center for Brain Science (CBS) have shown that a deficit in histone methylation could lead to the development of autism spectrum disorder (ASD), in the process identifying a direct link between the SUV39H2 gene and ASD. Their results have been published in the journal Molecular Psychiatry.

Genes are turned on and off throughout our development, but genetic variation means that what is turned off in some people remains turned on in others. This is why, for example, some adults can digest dairy products and others are lactose intolerant; the gene for making the enzyme lactase is turned off when some people become adults, but not others. One way that genes can be turned on and off is through a process called histone methylation, in which special enzymes transfer methyl groups to histone proteins that are wrapped around DNA.

Variations in genes related to methylation during brain development can lead to serious problems. One such variation occurs in a rare disorder called Kleefstra syndrome, in which a mutation prevents methylation of H3K9 — a specific location on histone H3. Because Kleefstra syndrome resembles autism in some ways, RIKEN CBS researchers led by Takeo Yoshikawa looked for autism-specific variations in genes that can modify H3K9. Among nine such genes, they found one variant in an H3K9 methyltransferase gene — SUV39H2 — that was present in autism, and the mutated SUV39H2 prevented methylation when tested in the lab. Similar loss-of-function results were found for the mouse version of the variant.

The next step was to see what happens in mice that lack the Suv39h2 gene. Behaviourally, the researchers found that the mice could learn a simple cognitive task, but had difficultly when the task required cognitive flexibility. In the simple task, mice learned to get a reward by poking a door at alternating diagonal corners of a cage. After they could do this well, the possible reward locations switched to the other two diagonal corners. The genetically modified mice did this as well as wild-type mice. In another task, after learning to alternate between the two diagonal corners, only the location of one reward was switched. When the mice were challenged to alternate randomly between these two tasks, wild-type mice could adapt quickly, but the Suv39h2-deficient mice took much longer.

“This serial reversal-learning task was essential,” said first author Shabeesh Balan. “Cognitive inflexibility is a core symptom of ASD, and our new task was able to address this behavioural feature in ways that previous mouse studies could not.”

When the researchers examined what happened in the mouse brain when H3K9 methylation failed to occur, they found that important genes that are usually silenced in early development were turned on in the experimental mice.

Suv39h2 is known to be expressed in early neurodevelopment and to methylate H3K9,” said Yoshikawa. “This keeps a check on genes that should be switched off. But without it, genes in the protocadherin β cluster were abnormally expressed at high levels in embryonic mice.” Because protocadherins are critical for the formation of neural circuits, the researchers believe they have found an important biological pathway that could be central to several neurodevelopmental disorders.

The team then verified the importance of SUV39H2 in human ASD by finding that its expression was lower in the post-mortem brains of people with ASD than of controls. According to Yoshikawa, “What began with a loss-of-function mutation in only one person with ASD has led to a general causal landscape for ASD that culminates in brain circuit abnormality.”

The study thus shows that activating the SUV39H2 gene is a potential therapy for mental disorders — including ASD — that should be investigated more thoroughly in future.

Image credit: ©

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related Articles

Outsourcing single-use technologies to accelerate speed to market

To fast-track time to market and gain a competitive edge, pharmaceutical development companies...

Intestinal drug found to boost memory and cognition

An existing drug — used to treat constipation — may be able to boost our ability to...

Opioids could treat inflammatory bowel disease

KNT-127 — a drug that targets delta opioid receptors — can reduce pro-inflammatory...

  • All content Copyright © 2021 Westwick-Farrow Pty Ltd